CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 148 enrolled
Drug / intervention
pazopanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00297258
NCT00297258Phase 2Completed
CompareCT.gov

Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma

GlaxoSmithKline·interventional·Posted Feb 28, 2006·Updated Feb 3, 2016

In Brief

A Phase 2 clinical trial evaluating pazopanib for Sarcoma, Soft Tissue. Completed, enrolled 148 participants across 16 sites in 5 countries.

Detailed Summary

The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Soft Tissue
CountriesBelgium, France, Hungary, Netherlands, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 28, 2006
Enrollment StartNov 1, 2005
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 20.3 years ago

Interventions

pazopanibdrug

oral tablet